RELATING TO INSURANCE -- PHARMACY FREEDOM OF CHOICE -- FAIR, COMPETITION AND PRACTICES
Impact
The proposed legislation seeks to amend existing regulations under the Rhode Island General Laws concerning pharmacy practices. By stressing the need for PBMs to respect prescriber choices, the bill could increase access to necessary medications for patients. The implications for state laws include a potential shift in the authority and responsibility of PBMs, as they would be held accountable for any denial or delay related to a prescriber's choice of drug, which is classified as an unlawful interference with medical practice. This could create a more patient-centric approach within the pharmaceutical system in Rhode Island.
Summary
House Bill H7817 aims to enhance patient rights regarding prescription drug coverage by prohibiting pharmacy benefits managers (PBMs) from denying coverage for medications prescribed by healthcare providers. The bill mandates that PBMs must accept and honor the prescription drug selected by the prescriber for a patient, thereby aiming to ensure that decisions about patient treatment are guided by healthcare professionals rather than insurance cost-containment policies. This act addresses concerns about PBMs making arbitrary decisions that can negatively impact patient health outcomes.
Contention
While the bill is seen by supporters as a necessary step towards fair competition and practices in pharmacy, it may face opposition from PBMs and insurance companies concerned about increased costs and lack of control over formulary decisions. The dialogue surrounding H7817 may be influenced by arguments regarding the balance between cost management, patient rights, and the operational capacities of PBMs. Key stakeholders including healthcare providers, patients, and insurance representatives will likely continue to engage in discussions to address the effects this legislation could have on prescription medication access.
Adds new sections that set forth conditions for pharmacists to prescribe tobacco cessation drug therapies, including education approved by state board of pharmacy. The cessation therapies to be covered by all health insurance carriers on or after 1/1/26.
Adds new sections that set forth conditions for pharmacists to prescribe tobacco cessation drug therapies, including education approved by state board of pharmacy. The cessation therapies to be covered by all health insurance carriers on or after 1/1/26.
Provides certain controls over prescription drug costs by imposing transparency, oversight and accountability requirements on commercial insurers and their pharmacy benefit managers.
Provides certain controls over prescription drug costs by imposing transparency, oversight and accountability requirements on commercial insurers and their pharmacy benefit managers.
Requires the secretary of the executive office of health and human services to monitor and mandate changes to the price-setting practices of pharmacy benefit managers to prohibit the spread pricing payment model.